The Federal Trade Commission (FTC has announced a significant crackdown on falsely-marketed CBD products, Operation CBDeceit.
CBD companies that the FTC targeted market oils, balms, gummies, and coffee. These companies claimed that their products could treat heart disease, Alzheimer's, hypertension, or cancer.
Many CBD companies do not realize the importance of all content related to their products, such as labels, emails, social media, and websites. False claims can make them liable. For example, brands must not make claims about CBD's ability to treat certain conditions to avoid being punished and called out by the FTC. This will damage the brand's reputation as well as consumer trust.
In a statement, Andrew Smith, Director of FTC's Bureau of Consumer Protection, stated that the six settlements announced today send a clear signal to the CBD industry's burgeoning CBD market: Don't make false health claims that can't be supported by science. "Also, don't be surprised to hear from FTC.
Each company will be required to remove any false labels by the FTC. In addition, a portion of these companies will also have to pay the penalty to the FTC. Bionatrol Health, LLC, CBD Meds, Inc., Epichouse LLC (First Class Herbalist CBD), and Bionatrol Health, LLC were among the companies.
Steves Distributing, LLC will pay $75,000 to the FTC for misleading health claims.
Operation CBDeceit marks the FTC's first crackdown on the CBD industry. There are plans to expand the operation in the future. The federal government is finally stepping in to regulate the CBD industry, which is growing rapidly.
CBD users will become more educated and know what to watch out for. It is in both the best interests of consumers and brand integrity and the industry's overall health to not overpromise CBD effects. Instead, focus on quality products.
Image Credit: Clker-Free-Vector-Images
Image Source: https://pixabay.com/vectors/federal-trade-commission-seal-36081/
Article credit to https://cbdhealthandwellness.net
